[go: up one dir, main page]

AR096113A1 - Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados - Google Patents

Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados

Info

Publication number
AR096113A1
AR096113A1 ARP140101738A ARP140101738A AR096113A1 AR 096113 A1 AR096113 A1 AR 096113A1 AR P140101738 A ARP140101738 A AR P140101738A AR P140101738 A ARP140101738 A AR P140101738A AR 096113 A1 AR096113 A1 AR 096113A1
Authority
AR
Argentina
Prior art keywords
polypeptides
rsv
prefusion
synchrical
viruses
Prior art date
Application number
ARP140101738A
Other languages
English (en)
Inventor
Petrus Maria Langedijk Johannes
Krarup Anders
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48326107&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096113(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR096113A1 publication Critical patent/AR096113A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Polipéptidos F de prefusión del virus sincicial respiratorio (RSV) estables, composiciones inmunogénicas que comprenden dichos polipéptidos y sus usos en la prevención y/o el tratamiento de una infección por RSV. Moléculas de ácido nucleico. Vector. Método para introducir mutaciones.
ARP140101738A 2013-04-25 2014-04-25 Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados AR096113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13165402 2013-04-25

Publications (1)

Publication Number Publication Date
AR096113A1 true AR096113A1 (es) 2015-12-09

Family

ID=48326107

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101738A AR096113A1 (es) 2013-04-25 2014-04-25 Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados

Country Status (33)

Country Link
US (3) US10899800B2 (es)
EP (2) EP2988780B1 (es)
JP (1) JP6469081B2 (es)
KR (1) KR102236497B1 (es)
CN (2) CN110590916A (es)
AP (1) AP2015008815A0 (es)
AR (1) AR096113A1 (es)
AU (1) AU2014259474B2 (es)
CA (1) CA2910067C (es)
CL (1) CL2015003124A1 (es)
CY (1) CY1121600T1 (es)
DK (1) DK2988780T3 (es)
EA (2) EA035522B1 (es)
ES (1) ES2715378T3 (es)
HR (1) HRP20190175T1 (es)
HU (1) HUE041659T2 (es)
IL (1) IL242186B (es)
LT (1) LT2988780T (es)
ME (1) ME03442B (es)
MX (1) MX361774B (es)
MY (2) MY181066A (es)
PE (1) PE20151867A1 (es)
PH (1) PH12015502377B1 (es)
PL (1) PL2988780T3 (es)
PT (1) PT2988780T (es)
RS (1) RS58436B1 (es)
SG (1) SG11201508567XA (es)
SI (1) SI2988780T1 (es)
SM (1) SMT201900138T1 (es)
TR (1) TR201902513T4 (es)
TW (1) TWI663175B (es)
WO (1) WO2014174018A1 (es)
ZA (1) ZA201507912B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2370099B1 (en) 2008-12-09 2016-04-20 Novavax, Inc. Modified rsv f proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
DK2988780T3 (en) * 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2016160166A1 (en) * 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EP3821906A1 (en) 2015-07-07 2021-05-19 Janssen Vaccines & Prevention B.V. Vaccine against rsv comprising modified f polypeptide
EP3344288A1 (en) * 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
EP3393512B1 (en) 2015-12-23 2025-11-19 Pfizer Inc. Rsv f protein mutants
EP3411028B1 (en) * 2016-02-03 2021-05-05 Janssen Sciences Ireland Unlimited Company Combination product for treating or ameliorating respiratory syncytial virus infection
US11174292B2 (en) 2016-03-29 2021-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion RSV F proteins and their use
MA52910A (fr) * 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs
WO2017174564A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
EP3464331B1 (en) * 2016-05-30 2020-10-28 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
MA47787A (fr) 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
EP3606942B1 (en) 2017-04-04 2025-06-11 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CA3061278A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
EP3658118B1 (en) 2017-07-24 2025-03-19 Novavax, Inc. Methods and compositions for treating respiratory disease
CA3073790A1 (en) * 2017-09-15 2019-03-21 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against rsv
KR102700187B1 (ko) * 2017-09-29 2024-08-28 에스케이바이오사이언스(주) 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
US12370252B2 (en) * 2018-10-29 2025-07-29 Emory University RSV virus-like particles and methods of use thereof
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
CN109851678A (zh) * 2019-03-07 2019-06-07 苏州宇之波生物科技有限公司 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
JP2022532723A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN111303245B (zh) * 2020-02-21 2023-06-27 成都奥达生物科技有限公司 一种抗合胞病毒膜融合抑制剂
BR112022019411A2 (pt) 2020-04-02 2022-12-06 Janssen Vaccines & Prevention Bv Composições de vacina estabilizadas
IL299515A (en) 2020-06-29 2023-02-01 Janssen Vaccines & Prevention Bv Vaccine combination against respiratory syncytial virus infection
CN112220921B (zh) 2020-08-25 2022-08-16 北京交通大学 一种针对呼吸道合胞病毒感染的组合疫苗
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
CN114195867B (zh) * 2021-12-15 2024-05-03 北京交通大学 一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
EP4578870A1 (en) * 2022-09-29 2025-07-02 Beijing Benewill Technology Development Co., Ltd. Respiratory syncytial virus recombinant fusion protein with prefusion conformation, and preparation method therefor and use thereof
EP4593876A2 (en) 2022-09-29 2025-08-06 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
IL320459A (en) 2022-10-27 2025-06-01 Pfizer Rna molecules encoding rsv-f and vaccines containing them
WO2024089634A1 (en) 2022-10-27 2024-05-02 Pfizer Inc. Immunogenic compositions against influenza and rsv
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
EP4652184A2 (en) * 2023-01-17 2025-11-26 The Scripps Research Institute Engineered paramyxovirus soluble fusion (f) proteins and related vaccines
AU2024209772A1 (en) 2023-01-18 2025-06-26 Pfizer Inc. Vaccines against respiratory diseases
US20240287544A1 (en) * 2023-02-06 2024-08-29 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
WO2024251281A1 (zh) 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
US20250135006A1 (en) 2023-07-07 2025-05-01 Pfizer Inc. Amphiphilic tlr7/8 adjuvants and uses thereof
CN119462859A (zh) * 2023-08-09 2025-02-18 深圳瑞吉生物科技有限公司 呼吸道合胞病毒抗原性多肽、疫苗及其应用
CN116785421B (zh) * 2023-08-21 2024-01-09 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种牛呼吸道合胞体病毒的mRNA疫苗及其应用
CN119569835A (zh) * 2023-09-07 2025-03-07 北京科兴中维生物技术有限公司 呼吸道合胞病毒f蛋白及其应用
US20250188131A1 (en) * 2023-09-15 2025-06-12 Icosavax, Inc. Viral proteins and nanostructures and uses thereof
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
CN117736278B (zh) * 2023-12-25 2025-02-07 英诺特（唐山）生物技术有限公司 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法
TW202536184A (zh) * 2024-01-11 2025-09-16 大陸商嘉晨西海（杭州）生物技術有限公司 呼吸道融合病毒疫苗組合物及其用途
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
CN121022942A (zh) * 2024-05-27 2025-11-28 广州国家实验室 腺相关病毒载体在制备防治rsv感染和/或rsv引起的疾病的药物中的应用
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
CN120192386A (zh) * 2025-02-07 2025-06-24 复星安特金(成都)生物制药有限公司 Rsv f蛋白突变体及其应用

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
CA2192442C (en) 1994-06-10 2007-09-25 Imre Kovesdi Complementary adenoviral vector systems and cell lines
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
ATE278794T1 (de) 1995-06-15 2004-10-15 Crucell Holland Bv Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2177085C (en) 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
BR9710030A (pt) 1996-07-01 1999-08-10 Rhone Poulenc Rorer Sa Processo de produção de adenovírus recombinantes processo de purificação de adenovírus recombinantes a partir de um meio biológico preparação viral purificada composição farmacêutica e utilização de iodixanol-5,5'-[(2-Hidroxipropil-1,3-Propanottl)-Bis[N,N'-Bis(2,3-Didroxipropil-2,4,6-Triodo-1,3-Benzenocarboxamida]
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4492826B2 (ja) 1996-11-20 2010-06-30 イントロジェン セラピューティクス，インコーポレイテッド アデノウイルスベクターの産生および精製のための改良された方法
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
ATE341614T1 (de) 1998-02-17 2006-10-15 Schering Corp Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
EP1977764A1 (en) 1998-11-16 2008-10-08 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE485382T1 (de) 1999-05-17 2010-11-15 Crucell Holland Bv Rekombinantes adenovirus des ad26-serotyps
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
EP1287159A4 (en) 2000-05-08 2005-02-09 Davisco Foods Int Inc Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals
AUPR878401A0 (en) 2001-11-09 2001-12-06 Biota Holdings Ltd Methods for identifying or screening anti-viral agents
JP4550421B2 (ja) 2001-12-12 2010-09-22 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド ウイルスの保存のための組成物
US20030232018A1 (en) 2002-01-18 2003-12-18 Berlex Biosciences Stabilized formulations of adenovirus
US20030180936A1 (en) 2002-03-15 2003-09-25 Memarzadeh Bahram Eric Method for the purification, production and formulation of oncolytic adenoviruses
SI1497440T1 (sl) 2002-04-25 2009-02-28 Crucell Holland Bv Stabilni adenovirusni vektorji in postopki za njihovo propagacijo
AU2003271737B2 (en) 2002-04-25 2007-04-19 Crucell Holland B.V. Means and methods for the production of adenovirus vectors
ES2285120T3 (es) 2002-05-14 2007-11-16 MERCK & CO., INC. Procedimientos de purificacion de adenovirus.
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CA2496918A1 (en) 2002-08-28 2004-03-11 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
WO2005080556A2 (en) 2004-02-23 2005-09-01 Crucell Holland B.V. Virus purification methods
CA2602944C (en) 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
EP1998804B1 (en) 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
EP2099486A2 (en) 2006-11-30 2009-09-16 Government Of The United States Of America, As Represented by the Secretary Codon modified immunogenic compositions and methods of use
US7901388B2 (en) 2007-07-13 2011-03-08 Bacoustics, Llc Method of treating wounds by creating a therapeutic solution with ultrasonic waves
PL2222710T3 (pl) * 2007-12-24 2017-01-31 Id Biomedical Corporation Of Quebec Rekombinowane antygeny rsv
WO2010014975A2 (en) 2008-08-01 2010-02-04 Academia Sinica Use of microrna signatures for assessing risk levels of neuroblastoma patients
EA019928B1 (ru) 2008-11-03 2014-07-30 Круселл Холланд Б.В. Способ получения аденовирусных векторов
JP5882741B2 (ja) 2009-02-02 2016-03-09 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
EP3178490B1 (en) * 2009-07-15 2022-04-20 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
ES2553440T3 (es) 2009-08-13 2015-12-09 Crucell Holland B.V. Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
MX2012004221A (es) 2009-10-15 2012-06-08 Crucell Holland Bv Proceso para purificacion de adenovirus de cultivos de alta densidad celular.
WO2011045378A1 (en) 2009-10-15 2011-04-21 Crucell Holland B.V. Method for the purification of adenovirus particles
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
BR112012019023B1 (pt) 2010-02-15 2021-12-21 Janssen Vaccines & Prevention B.V. Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator
CN103097412B (zh) 2010-07-09 2016-08-10 克鲁塞尔荷兰公司 抗人呼吸道合胞病毒(rsv)抗体以及使用方法
SI3275892T1 (sl) * 2011-05-13 2020-06-30 Glaxosmithkline Biologicals S.A. Prefuzijski RSV F antigeni
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
NZ630753A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
JP2013247240A (ja) 2012-05-25 2013-12-09 Gigaphoton Inc レーザ装置
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
HRP20240996T1 (hr) 2013-03-13 2024-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefuzija rsv f proteina i njihova uporaba
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US10035842B2 (en) 2013-04-15 2018-07-31 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
EP2986637A1 (en) 2013-04-15 2016-02-24 Crucell Holland B.V. Human antibodies binding to rsv g protein
DK2988780T3 (en) 2013-04-25 2019-04-08 Janssen Vaccines & Prevention Bv STABILIZED SOLVEN RSV-F PREFUSION POLYPTIDES
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
TR201900274T4 (tr) 2013-09-19 2019-02-21 Janssen Vaccines & Prevention Bv Geliştirilmiş adenovirüs formülasyonları.
WO2017174564A1 (en) * 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
MA52910A (fr) * 2016-04-05 2021-04-21 Janssen Vaccines & Prevention Bv Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'un infection vrs

Also Published As

Publication number Publication date
CA2910067C (en) 2023-10-17
TWI663175B (zh) 2019-06-21
AU2014259474A1 (en) 2015-11-05
CN105188745A (zh) 2015-12-23
CN105188745B (zh) 2019-10-18
JP6469081B2 (ja) 2019-02-13
MX361774B (es) 2018-12-17
ES2715378T3 (es) 2019-06-04
JP2016520039A (ja) 2016-07-11
CY1121600T1 (el) 2020-05-29
EP2988780A1 (en) 2016-03-02
HUE041659T2 (hu) 2019-05-28
NZ713371A (en) 2021-02-26
PE20151867A1 (es) 2016-01-07
HRP20190175T1 (hr) 2019-03-22
SG11201508567XA (en) 2015-11-27
TR201902513T4 (tr) 2019-03-21
EP2988780B1 (en) 2018-12-26
US20230265127A1 (en) 2023-08-24
PH12015502377A1 (en) 2016-02-22
SI2988780T1 (sl) 2019-05-31
AP2015008815A0 (en) 2015-10-31
AU2014259474B2 (en) 2018-09-13
SMT201900138T1 (it) 2019-05-10
CN110590916A (zh) 2019-12-20
LT2988780T (lt) 2019-03-12
CA2910067A1 (en) 2014-10-30
MX2015014890A (es) 2016-03-09
RS58436B1 (sr) 2019-04-30
PH12015502377B1 (en) 2021-09-08
PL2988780T3 (pl) 2019-06-28
MY181066A (en) 2020-12-17
KR20160002938A (ko) 2016-01-08
KR102236497B1 (ko) 2021-04-06
WO2014174018A1 (en) 2014-10-30
EP3488864A1 (en) 2019-05-29
US10899800B2 (en) 2021-01-26
US20210101940A1 (en) 2021-04-08
PT2988780T (pt) 2019-03-25
ME03442B (me) 2020-01-20
TW201520221A (zh) 2015-06-01
DK2988780T3 (en) 2019-04-08
US20160102123A1 (en) 2016-04-14
EA039803B1 (ru) 2022-03-15
MY201791A (en) 2024-03-18
EA201592048A1 (ru) 2016-04-29
CL2015003124A1 (es) 2016-05-13
EA202090675A3 (ru) 2020-08-31
HK1220124A1 (en) 2017-04-28
EA202090675A2 (ru) 2020-06-30
ZA201507912B (en) 2022-03-30
EA035522B1 (ru) 2020-06-29
IL242186B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
CY1125368T1 (el) Εμβολια κατα των ιων του αναπνευστικου συστηματος
CL2015003655A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
ECSP21042554A (es) Proteínas f de prefusión del vrs estabilizadas
MX2018012094A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
PH12018500856A1 (en) Respiratory syncytial virus vaccine
BR112017028449A2 (pt) polipeptídeos rsv f pré-fusão solúveis estabilizados
EA201890204A1 (ru) Антибактериальные соединения
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201990043A1 (ru) Антибактериальные соединения
AR091316A1 (es) Moleculas de union humanas que se pueden unir y neutralizar a los virus de la influenza b y sus usos
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
BR112018074483A2 (pt) proteínas f do rsv pré-fusão estabilizadas
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
IL266279B1 (en) Stable aqueous capsaicin injectable formuatlions and medical uses thereof
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
AR095869A1 (es) Anticuerpos humanos que se unen a la proteína g del rsv
TH158929A (th) พิวรีนแบบวงใหญ่สำหรับรักษาการติดเชื้อจากไวรัส
DK3344259T3 (da) Sammensætning og medicinsk anordning, som omfatter acetylsalicylsyre til behandling af hudinfektioner med menneskelig papillomavirus
AR095501A1 (es) Vacunas rsv

Legal Events

Date Code Title Description
FC Refusal